Research Analysts’ Weekly Ratings Updates for Sutro Biopharma (STRO)

Several brokerages have updated their recommendations and price targets on shares of Sutro Biopharma (NASDAQ: STRO) in the last few weeks:

• 11/15/2023 – Sutro Biopharma had its price target lowered by analysts at Piper Sandler from $18.00 to $12.00. They now have an “overweight” rating on the stock.
• 11/14/2023 – Sutro Biopharma had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $12.00 price target on the stock.
• 11/14/2023 – Sutro Biopharma had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
• 11/9/2023 – Sutro Biopharma is now covered by analysts at Deutsche Bank Aktiengesellschaft. They set a “buy” rating and a $12.00 price target on the stock.
• 10/23/2023 – Sutro Biopharma had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $12.00 price target on the stock.
• 10/5/2023 – Sutro Biopharma is now covered by analysts at Oppenheimer Holdings Inc.. They set an “outperform” rating and a $10.00 price target on the stock.

Sutro Biopharma Stock Performance

Shares of Sutro Biopharma stock traded up $0.08 during trading on Monday, hitting $2.77. The company’s stock had a trading volume of 889,618 shares, compared to its average volume of 500,612. Sutro Biopharma, Inc. has a 52 week low of $2.01 and a 52 week high of $8.72. The company has a market capitalization of $168.84 million, a PE ratio of -0.95 and a beta of 0.90. The company has a fifty day simple moving average of $3.20 and a two-hundred day simple moving average of $4.26.

Insider Activity at Sutro Biopharma

In other Sutro Biopharma news, insider Brunilda Shtylla sold 15,428 shares of the business’s stock in a transaction on Monday, August 28th. The stock was sold at an average price of $4.71, for a total value of $72,665.88. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 6.90% of the stock is owned by corporate insiders.

Institutional Trading of Sutro Biopharma

Several institutional investors have recently added to or reduced their stakes in the business. American Century Companies Inc. boosted its holdings in Sutro Biopharma by 14.3% in the first quarter. American Century Companies Inc. now owns 14,656 shares of the company’s stock worth $66,000 after purchasing an additional 1,833 shares during the last quarter. The Manufacturers Life Insurance Company grew its position in Sutro Biopharma by 9.9% in the 4th quarter. The Manufacturers Life Insurance Company now owns 20,667 shares of the company’s stock worth $167,000 after purchasing an additional 1,864 shares during the period. Principal Financial Group Inc. grew its position in Sutro Biopharma by 13.9% in the 1st quarter. Principal Financial Group Inc. now owns 15,348 shares of the company’s stock worth $71,000 after purchasing an additional 1,874 shares during the period. American International Group Inc. grew its position in Sutro Biopharma by 9.8% in the 4th quarter. American International Group Inc. now owns 25,500 shares of the company’s stock worth $206,000 after purchasing an additional 2,273 shares during the period. Finally, Prudential Financial Inc. grew its position in Sutro Biopharma by 24.2% in the 1st quarter. Prudential Financial Inc. now owns 14,390 shares of the company’s stock worth $66,000 after purchasing an additional 2,800 shares during the period. 89.40% of the stock is currently owned by hedge funds and other institutional investors.

Sutro Biopharma, Inc operates as a clinical-stage oncology company. It develops site-specific and novel-format antibody drug conjugates (ADC) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. The company's product candidates include STRO-001, an ADC directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials.